Biocartis names chief executive officer

Nayan Gregory Parekh takes up role as current ceo becomes executive chairman

Biocartis, a Swiss developer of compact molecular diagnostic (MDx) systems, has appointed Dr Nayan Gregory Parekh as its new chief executive.

Parekh brings to Biocartis a wealth of pharmaceutical and biotechnology industry experience and has been an executive director of the Board since April 2011.

Rudi Pauwels, co-founder of Biocartis and current ceo, will become executive chairman and = concentrate on the company’s scientific and technology strategy.

Parekh has held senior management positions at Novartis and Deutsche Bank and has a broad network of relationships and experience across a number of healthcare fields and geographies.

Most recently, he was at New Rhein Healthcare, a healthcare investment firm where he was one of the founding partners. Before setting up New Rhein, he spent six years as head of corporate development at Novartis.

Prior to joining Novartis in 2004, Parekh spent ten years in investment banking, primarily focusing on the pharmaceutical and biotechnology sectors.

You may also like

Research & Development

Biocartis and BMS to collaborate on MSI testing with immuno-oncology therapies

Biocartis Group has signed a collaboration agreement with Bristol-Myers Squibb to register and use the Idylla MSI test in connection with immuno-oncology therapies
Finance

Biocartis raises €55.5 million to diversify its automated PCR machine

Funds have been raised by molecular diagnostics company to expand and diversify their PCR platform, Idylla
Research & Development

Biocartis and Amgen sign a RAS biomarker testing collaboration in Europe

Biocartis, an innovative molecular diagnostics company, has signed a new collaboration agreement with Amgen, a leading biotechnology company
Infection Control

Biocartis develops rapid Ebola virus triage test

Developed for Idylla platform the test aims at fast and accurate diagnostics in challenging environments
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Analysis

Anton Paar’s new PNR 500 sets benchmark in automated penetrometry

The instrument determines how far a standardised test body, such as a cone or needle, penetrates a sample under defined conditions
Analysis

Anton Paar expands Litesizer portfolio with cost-effective DLS 301 for routine analysis

Designed as a budget-friendly solution for routine analysis, the new instrument provides reliable performance for laboratories working with simpler samples and straightforward quality control workflows
Subscribe now